Inogen (INGN) just unveiled an announcement.
Inogen, Inc. has finalized a separation agreement with Dr. Stanislav Glezer, who served as the Executive Vice President, R&D, and Chief Medical Officer. His official separation from the company was effective on April 11, 2024, with severance benefits aligned with his previous employment agreement. This agreement is a significant development for stakeholders tracking leadership changes within Inogen, Inc.
For a thorough assessment of INGN stock, go to TipRanks’ Stock Analysis page.
